Dasetta 1/35 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Dasetta 1/35 28 Day Availability in 2026

If your patients have been calling about trouble filling Dasetta 1/35 28 Day prescriptions, you're seeing a pattern that's affecting practices across the country. While Dasetta 1/35 (Norethindrone 1 mg / Ethinyl Estradiol 0.035 mg) isn't in a formal FDA-listed shortage, real-world availability has been inconsistent — and patients are feeling the impact.

This briefing covers what you need to know about Dasetta 1/35 availability, practical prescribing strategies, equivalent alternatives, cost considerations, and tools that can help your patients access their medication.

Timeline: How We Got Here

Dasetta 1/35 28 Day, manufactured by Northstar Rx LLC (a Cipla subsidiary), has been on the U.S. market as a generic equivalent to Ortho-Novum 1/35 and Norinyl 1+35. The medication has not been subject to a formal recall or FDA-listed shortage.

However, the generic oral contraceptive landscape has shifted considerably:

• 2020–2022: COVID-related supply chain disruptions affected pharmaceutical manufacturing globally. While oral contraceptives were largely spared from acute shortages, distribution patterns shifted as wholesalers consolidated suppliers.
• 2023–2024: Increased demand for oral contraceptives — driven partly by policy discussions around reproductive healthcare access — put pressure on pharmacy-level inventories. Some generic brands became harder to source at individual pharmacies.
• 2025–2026: The market has stabilized at the manufacturing level, but pharmacy stocking decisions continue to create brand-specific availability gaps. Patients prescribed Dasetta 1/35 specifically may find their pharmacy carries Nortrel 1/35 or Alyacen 1/35 instead.

Prescribing Implications

The key clinical consideration is that all Norethindrone 1 mg / Ethinyl Estradiol 0.035 mg monophasic products are FDA-rated as therapeutically equivalent (AB-rated). From a pharmacological standpoint, patients should experience no difference in efficacy or safety when switching between brands.

However, prescribers should be aware of these practical considerations:

Generic Substitution Rules

In most states, pharmacists can substitute one AB-rated generic for another unless the prescriber writes "Dispense As Written" (DAW). If you write prescriptions for "Norethindrone/Ethinyl Estradiol 1/35" without specifying a brand, pharmacists have maximum flexibility to fill with whatever equivalent they stock.

Patient Concerns About Brand Switching

Some patients express anxiety about switching brands, even when the active ingredients are identical. While inactive ingredient differences (dyes, fillers, binders) are generally clinically insignificant, patients with specific sensitivities or allergies to certain inactive ingredients may have legitimate concerns. A brief conversation reassuring patients about therapeutic equivalence — while validating their experience — goes a long way.

Prescribing Tip

Consider writing prescriptions generically: "Norethindrone 1 mg / Ethinyl Estradiol 0.035 mg, 28-day pack" rather than specifying Dasetta 1/35. This gives pharmacists the most flexibility and reduces the likelihood of patients being told their prescription can't be filled.

Availability Picture: Equivalent Products

The following products are therapeutically equivalent to Dasetta 1/35 28 Day:

• Nortrel 1/35 — Teva Pharmaceuticals (widely distributed)
• Alyacen 1/35 — Glenmark Pharmaceuticals
• Necon 1/35 — Actavis/Allergan
• Cyclafem 1/35 — Lupin Pharmaceuticals
• Pirmella 1/35 — Lupin Pharmaceuticals
• Nylia 1/35 — Northstar Rx

If a patient needs a different formulation entirely, consider:

• Dasetta 7/7/7 — Triphasic version (Norethindrone 0.5/0.75/1 mg with Ethinyl Estradiol 0.035 mg)
• Sprintec (Norgestimate/Ethinyl Estradiol) — different progestin, widely available
• Lo Loestrin Fe — lower estrogen dose option (Ethinyl Estradiol 0.01 mg)
• Levora / Levlen (Levonorgestrel/Ethinyl Estradiol) — different progestin

For a patient-facing version of this information, see Alternatives to Dasetta 1/35 28 Day.

Cost and Access Considerations

Under the ACA contraceptive coverage mandate, most commercial insurance plans cover oral contraceptives at $0 copay. Dasetta 1/35 and its equivalents typically sit on Tier 1 (preferred generic) formularies with no prior authorization required.

For uninsured patients, pricing is generally favorable:

• Retail price: $35–$61 per 28-tablet pack
• With GoodRx coupon: As low as $9.96
• With SingleCare: Approximately $10.99
• Telehealth services (Nurx, Pandia Health): $15–$23 per pack with free delivery

Patients without insurance should be directed to discount programs. Our patient savings guide covers all available options.

For patients facing financial hardship, Title X-funded clinics and Planned Parenthood locations often provide oral contraceptives at no cost or on a sliding fee scale.

Tools and Resources for Your Practice

Medfinder for Providers is a free tool that helps you and your staff check real-time pharmacy availability of Dasetta 1/35 and other medications. This can be integrated into your workflow when patients report difficulty filling prescriptions:

1. Search for Dasetta 1/35 (or Norethindrone/Ethinyl Estradiol 1/35) on medfinder.com/providers
2. Identify nearby pharmacies with current stock
3. Send the prescription directly to a pharmacy that has it available

This reduces phone tag between your office, the patient, and multiple pharmacies — saving everyone time.

Looking Ahead

The oral contraceptive market is evolving. Key trends to watch:

• OTC contraceptive access: The FDA approved Opill (Norgestrel 0.075 mg) for over-the-counter sale. While this is a progestin-only pill (not the same as Dasetta 1/35's combination formula), it provides an additional access point for patients who have trouble getting prescriptions filled.
• Telehealth expansion: More patients are using direct-to-consumer telehealth for contraceptive prescriptions, which may reduce local pharmacy demand pressure.
• Generic consolidation: As manufacturers consolidate, the number of distinct brands may decrease, potentially simplifying stocking decisions but also increasing vulnerability to supply disruptions from any single manufacturer.

Final Thoughts

Dasetta 1/35 28 Day availability issues in 2026 are primarily a distribution and stocking problem rather than a manufacturing shortage. Prescribing generically, educating patients about therapeutic equivalence, and using tools like Medfinder for Providers can help ensure your patients maintain uninterrupted access to their oral contraceptive.

Related provider resources: How to Help Your Patients Find Dasetta 1/35 in Stock · How to Help Patients Save Money on Dasetta 1/35